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Abstract 
Familial amyloid polyneuropathy (FAP) is a group of disorders characterized by the 
extracellular deposition of amyloid substance in various tissues. The peripheral nervous 
system and the heart are the main target organs, but the eye may also be involved. We 
report a case of vitreous amyloidosis as the first manifestation of FAP in a 66-year-old 
Portuguese man without a family history. © 2014 S. Karger AG, Basel 
Introduction 
Familial amyloid polyneuropathy (FAP) is an inherited disorder with autosomal domi-
nant transmission, characterized by systemic extracellular accumulation of amyloid fibrils 
[1]. The most common type of FAP is related to transthyretin (TTR), a protein that carries 
thyroxine and vitamin A [2]. Plasma-circulating TTR is mainly synthesized in the liver, but 
there is also production in the retinal pigment epithelium and in the choroid plexus [3, 4]. 
The clinical expression is variable among different mutations and different populations, and 
even the same population with the same mutation can present significant variability. The age 
of onset varies between the 20s and the 90s. The peripheral nerves and the heart are the 
organs most frequently affected [5]. 
More than 100 mutations have been related to FAP, but one point mutation in which a 
methionine residue replaces the valine residue at position 30 (TTR Val30Met) is particularly 
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frequent and is associated with several large foci around the world, namely Portugal, Japan, 
Sweden and the Balearic Islands [6–9]. This condition was first described in Portugal in 
1952, when Andrade [10] reported a peculiar neuropathy characterized by ascending 
sensory-motor loss and severe autonomic dysfunction, affecting patients of both genders 
between 25 and 35 years of age. 
Vitreous involvement was mentioned for the first time by Kantarjian and DeJong [11] in 
1953 in two siblings with FAP. The first description of the Swedish focus in 1968 also 
reported the occurrence of vitreous opacities along with the typical sensory, motor and 
autonomic neuropathy with onset at a later age if compared with Portuguese and Japanese 
patients [12]. In Portugal, vitreous opacities have rarely been described in patients with the 
natural and fatal course of the disease [13], but the prolonged survival after liver transplant 
led to a significant increase in the prevalence of this problem [14, 15]. 
Ocular manifestations of FAP include abnormal conjunctival vessels, keratoconjunctivi-
tis sicca, irregularities on lens surface and border of the pupil, change of pupillary shape and 
light reflex, vitreous opacities and glaucoma [16, 17]. Vitreous deposits of amyloid may be 
seen as one manifestation among other signs of the disease, but it has also been described as 
the earliest, isolated symptom of the disease [18–20]. 
We report a case of vitreous opacities as the initial manifestation of FAP TTR Val30Met 
in a late-onset Portuguese patient without a history of FAP. 
Case Report 
An apparently healthy 66-year-old man, born in Santa Maria da Feira and resident in 
Vila Nova de Gaia, Portugal, was first examined in March 2010 for right blurred vision and 
floaters. Symptoms were progressing for 2 months. Best-corrected visual acuity was 20/30 
in the right eye and 20/20 in the left eye. The anterior segment of both eyes was unremark-
able, with no abnormal conjunctival vessels, no change of pupillary shape, and no amyloid 
deposition at pupillary border or lens surface. Intraocular pressure, ocular movements and 
pupillary reflexes were normal. Vitreous yellowish-white opacities precluding examination 
of the fundus were identified in the right eye. The vitreous and retina of the left eye were 
normal. 
Full clinical evaluation showed an asymptomatic first-degree atrioventricular (AV) block 
in the absence of other neurologic or cardiac signs of disease. The mutation TTR Val30Met 
was identified by full sequencing of the gene, and a salivary gland biopsy was done but failed 
to show amyloid deposition. 
In November 2010, as the right visual acuity dropped to 20/100 the patient underwent 
a pars plana vitrectomy. The pathological examination of the surgical specimen which 
included Congo red stain showed material with yellowish-green birefringence consistent 
with amyloid. Postoperatively, best-corrected visual acuity was 20/20. In the summer of 
2011, the patient had several episodes of dizziness and fainting. A Mobitz 2 second-degree 
AV block was demonstrated with a Holter register and he was submitted to a pacemaker 
implantation, with complete recovery of these symptoms. In September 2012, the visual 
acuity decreased to 20/100 in both eyes. The right eye developed a cataract and the left eye 
presented vitreous opacities (fig. 1). At that time, the light pupillary reflex and the pupil 
shape were normal. Biomicroscopy of both eyes revealed no amyloid deposits on the lens 
surface or at the pupillary border. The intraocular pressure was normal. He was submitted 
to a phacoemulsification of the cataract with intraocular lens implantation in the right eye in 
September 2012. One month later, pars plana vitrectomy was performed in the left eye 
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without complications (fig. 2). In February 2013, his best-correct visual acuity of both eyes 
was 20/20, and the ophthalmological examination was normal, except for pseudophakia of 
the right eye. 
The patient remains free of neurologic symptoms or signs. There is no evidence of FAP 
in any of the patient’s relatives. His parents died very old without FAP manifestations. Nine 
siblings (1 brother, 1 sister and 7 half-brothers and half-sisters), 3 sons and 7 grandsons had 
no symptoms suggesting onset of the disease up to the time of reporting (fig. 3). 
Discussion 
FAP is a heterogeneous disease characterized by systemic accumulation of mutant amy-
loidogenic TTR in different tissues, including the eye. Portugal is the largest focus of the 
disease in the world, and it is related almost exclusively to the same mutation, TTR 
Val30Met. The age of onset shows a wide range (from 17 to 78 years), but 87% of patients 
developed symptoms before 40 years of age (mean 33.5 years of age) [6]. Nevertheless, our 
patient had a much later age of onset. 
Ocular manifestations commonly reported in FAP patients are abnormal conjunctival 
vessels, keratoconjunctivitis sicca, pupillary abnormalities, glaucoma and vitreous opacity. In 
a study with 37 Japanese patients, abnormal conjunctival vessels had the highest incidence 
with 100% after 10 years of follow-up, followed by the other abnormalities, with vitreous 
opacities reaching 17% in the same follow-up. It was also demonstrated that ocular 
manifestations increase with time [16, 21]. However, our patient had no other ocular 
manifestation except vitreous opacities, which are, when numerous, pathognomonic of the 
disease. In Portuguese FAP patients, vitreous opacities usually occur years after neurologic 
manifestations and are associated with other ocular changes, such as pupillary abnormali-
ties. 
Vitreous amyloid deposits are one of the main causes of decreased visual acuity in FAP 
patients. Although there are some reports describing isolated vitreous opacities, to the best 
of our knowledge, this is the first description of a similar case in a Portuguese patient. At 
least 20 mutations of TTR have been related to vitreous deposits, including TTR Val30Met, 
TTR Tyr114Cys, TTR Phe33Val, TTR Ile84Ser and TTR Ile84Asp [22]. In a report of Swedish 
homozygous Val30Met patients, all developed vitreous opacities [23]. In Portugal, the only 
mutation identified in patients with vitreous opacities was TTR Val30Met, as in our patient. 
Ideally, treatment of vitreous amyloidosis should remove the existing amyloid fibrils 
and prevent further amyloid deposition. Vitrectomy, which can be diagnostic and therapeu-
tic, is a safe and effective surgical treatment done when a significant visual morbidity is 
present [24]. Our patient improved to 20/20 visual acuity in both eyes after vitrectomy. The 
recurrence of vitreous opacities after vitrectomy has been described in some series [24, 25]. 
Beirão et al. [26] detected new amyloid deposits in all eyes submitted to nonextensive 
vitrectomy. This should be prevented with an extraction, as complete as possible, of vitreous, 
particularly behind the posterior capsule of lens. Koga et al. [24] suggest performing 
phacoemulsification and intraocular lens implantation because more extensive removal of 
the vitreous base is possible with lens removal. So far, our patient has had no recurrence. 
It is known that TTR, the precursor protein of amyloid, is predominantly synthesized by 
the liver. Primarily, it has been suggested that amyloid deposits in the vitreous because TTR 
can cross the blood-aqueous barrier [27]. However, there is evidence of TTR synthesis in the 
retinal pigment epithelium of the eye [3], and it has been proposed that vitreous amyloid 
deposition is the result of the local synthesis of the mutated TTR [28]. In a study of Kawaji et 
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al. [29] on rabbit eyes, it is suggested that ciliary pigment epithelium may also synthesize 
TTR in addition to the retinal pigment epithelium. The frequent occurrence of ocular 
amyloid deposition after liver transplantation confirms the importance of persistent local 
synthesis of mutated TTR [30]. 
Patients with the Val30Met mutation usually present sensory-dominant polyneuropathy 
(more commonly in lower limbs), autonomic disturbances and cardiac dysfunction. In the 
present case, an AV block needing a pacemaker implantation was the only systemic 
manifestation during the follow-up. This means the vitreous amyloid can be a signal of a 
potential severe systemic disease despite an absence of systemic manifestations, demon-
strating the importance of being alert to the whole system. This unusual presentation should 
not preclude the diagnosis because vitreous opacities are pathognomonic of amyloidosis. 
In conclusion, the ophthalmologist can have an important role as the first physician 
detecting typical manifestations of the disease. Ocular manifestations such as vitreous 
opacities and glaucoma lead to visual impairment and can potentially be addressed by 
surgery. An accurate and frequent follow-up evaluation is needed for the detection of ocular 
manifestations to ensure a good vision and quality of life of FAP patients. 
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Fig. 1. Retinography of the left eye. 
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Fig. 2. Vitrectomy of the left eye. 
 
 
 
Fig. 3. Family tree. 
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